Boji Medical's subsidiary gains approval for sodium sulfate

Boji Medical Technology Co., Ltd. (SZSE:300404) announced that its wholly-owned subsidiary, Guangzhou Huasheng Pharmaceutical Co., Ltd., has obtained approval for its sodium sulfate chemical raw material listing application. The approval, granted by the National Medical Products Administration, signifies that the product meets relevant drug registration requirements and can be produced and sold in the domestic market upon compliance with Good Manufacturing Practices (GMP). Sodium sulfate, a saline laxative used to promote bowel movements, is now registered under standard number YBY62712025, registration number Y20230000599 and acceptance number CYHS2360628, with a validity of 36 months until March 24, 2030. Boji Medical anticipates that this approval will broaden its business scope and enhance its competitiveness, however its effects on the company's financial performance for the current period are not expected to be significant.